Skip to main
PSNL

Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis Inc (PSNL) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 0%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Personalis Inc. has seen a positive trajectory in its stock, with a notable 28% increase following the announcement of Medicare coverage for its NeXT Personal MRD test in breast cancer, further indicating strong demand and market validation for its products. The company has made strategic adjustments to its business operations to enhance cash flow in anticipation of reimbursement outcomes, demonstrating prudent financial management. Additionally, the partnership with large commercial entities like Tempus and Merck indicates robust growth potential, with expected sales increases for 2026 and beyond, underscoring Personalis's long-term value and market opportunity in personalized cancer therapeutics.

Bears say

Personalis Inc. faces a negative outlook primarily due to a downward revision of its revenue guidance for Q4 2025, stemming from a slowdown in the biopharma sector and logistical issues with global sample management. The anticipated revenue decline of 12% to 5% year-over-year reflects challenges in predicting sample flow for minimal residual disease (MRD) testing and delays in reimbursement approvals, potentially impacting future cash flows. Additionally, an ongoing history of substantial losses and debt on the balance sheet raises concerns about the company’s ability to achieve and sustain profitability amidst these operational hurdles.

Personalis Inc (PSNL) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 0% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Personalis Inc (PSNL) Forecast

Analysts have given Personalis Inc (PSNL) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Personalis Inc (PSNL) has a Strong Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Personalis Inc (PSNL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.